Total Payments
$174,121
2024 Payments
$48,258
Companies
16
Transactions
172
Medicare Patients
1,196
Medicare Billing
$226,948
Payment Breakdown by Category
Consulting$147,392 (84.6%)
Travel$23,047 (13.2%)
Food & Beverage$3,682 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $147,392 | 57 | 84.6% |
| Travel and Lodging | $23,047 | 36 | 13.2% |
| Food and Beverage | $3,682 | 79 | 2.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $35,021 | 30 | $0 (2024) |
| GlaxoSmithKline, LLC. | $33,399 | 19 | $0 (2024) |
| Eisai Inc. | $32,166 | 31 | $0 (2024) |
| Merck Sharp & Dohme LLC | $31,840 | 25 | $0 (2024) |
| BioNTech SE | $16,768 | 13 | $0 (2024) |
| TESARO, Inc. | $10,439 | 15 | $0 (2019) |
| Clovis Oncology, Inc. | $7,118 | 19 | $0 (2019) |
| EMD Serono Research & Development Institute, Inc. | $2,130 | 1 | $0 (2024) |
| Daiichi Sankyo Inc. | $2,031 | 3 | $0 (2023) |
| ImmunoGen, Inc. | $1,569 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $48,258 | 38 | BioNTech SE ($13,618) |
| 2023 | $25,830 | 20 | GlaxoSmithKline, LLC. ($16,000) |
| 2022 | $19,742 | 13 | AstraZeneca Pharmaceuticals LP ($15,842) |
| 2021 | $15,002 | 8 | Eisai Inc. ($6,024) |
| 2020 | $21,955 | 24 | Eisai Inc. ($10,824) |
| 2019 | $21,406 | 33 | EISAI INC. ($8,908) |
| 2018 | $12,054 | 24 | Merck Sharp & Dohme Corporation ($6,471) |
| 2017 | $9,875 | 12 | TESARO, Inc. ($9,794) |
All Payment Transactions
172 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 11/18/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $335.83 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $136.25 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $48.00 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $45.98 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $545.05 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,416.19 | General |
| 10/28/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $4,880.00 | General |
| 10/09/2024 | BioNTech SE | — | Consulting Fee | Cash or cash equivalent | $3,250.00 | General |
| 09/16/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $47.61 | General |
| 09/16/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $24.43 | General |
| 09/15/2024 | ABBVIE INC. | ELAHERE (Drug) | Food and Beverage | In-kind items and services | $55.34 | General |
| Category: ONCOLOGY | ||||||
| 09/13/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $74.25 | General |
| 09/13/2024 | BioNTech SE | — | Travel and Lodging | In-kind items and services | $22.84 | General |
| 09/13/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $17.27 | General |
| 09/12/2024 | PFIZER INC. | TIVDAK (Biological) | Food and Beverage | In-kind items and services | $134.90 | General |
| Category: Oncology | ||||||
| 06/03/2024 | BioNTech SE | — | Food and Beverage | In-kind items and services | $19.15 | General |
| 06/01/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $143.26 | General |
| Category: Oncology | ||||||
| 05/22/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 04/24/2024 | Eisai Inc. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $2,445.00 | General |
| Category: Oncology | ||||||
| 03/25/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,425.00 | General |
| 03/18/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $64.00 | General |
| Category: Oncology | ||||||
| 03/17/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $27.62 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 338 | 607 | $221,890 | $60,080 |
| 2022 | 10 | 279 | 564 | $164,830 | $53,782 |
| 2021 | 8 | 245 | 471 | $164,110 | $54,730 |
| 2020 | 13 | 334 | 615 | $212,980 | $58,356 |
Total Patients
1,196
Total Services
2,257
Medicare Billing
$226,948
Procedure Codes
43
All Medicare Procedures & Services
43 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 55 | 180 | $55,510 | $18,681 | 33.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 59 | 148 | $32,310 | $10,015 | 31.0% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2023 | 12 | 12 | $37,680 | $8,448 | 22.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 51 | 51 | $23,670 | $6,426 | 27.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 35 | $11,200 | $3,115 | 27.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 45 | 63 | $9,035 | $2,788 | 30.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 19 | $9,785 | $2,404 | 24.6% |
| 38570 | Biopsy and removal of lymph nodes of abdominal cavity using an endoscope | Facility | 2023 | 11 | 11 | $19,580 | $2,187 | 11.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 37 | $7,955 | $2,152 | 27.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 20 | 24 | $7,440 | $2,050 | 27.5% |
| 38900 | Imaging of lymph nodes during surgery | Facility | 2023 | 12 | 12 | $5,700 | $1,279 | 22.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 11 | 15 | $2,025 | $537.04 | 26.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 56 | 177 | $50,705 | $19,012 | 37.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 56 | 174 | $34,960 | $12,776 | 36.5% |
| 58571 | Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | Facility | 2022 | 11 | 11 | $34,265 | $7,707 | 22.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 30 | 30 | $12,970 | $4,119 | 31.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 47 | 69 | $9,090 | $3,184 | 35.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 17 | 29 | $7,540 | $2,336 | 31.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 22 | 28 | $5,040 | $1,575 | 31.2% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 16 | 16 | $4,240 | $1,318 | 31.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 11 | 11 | $3,740 | $1,173 | 31.4% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 13 | 19 | $2,280 | $580.84 | 25.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 65 | 247 | $68,225 | $26,770 | 39.2% |
| 58571 | Abdominal removal of uterus (250 grams or less) with removal of tubes and/or ovaries using an endoscope | Facility | 2021 | 13 | 13 | $41,250 | $9,705 | 23.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 40 | 40 | $16,640 | $5,766 | 34.6% |
About Dr. Floortje Backes, MD
Dr. Floortje Backes, MD is a Obstetrics & Gynecology healthcare provider based in Hilliard, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/08/2007. The National Provider Identifier (NPI) number assigned to this provider is 1124231998.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Floortje Backes, MD has received a total of $174,121 in payments from pharmaceutical and medical device companies, with $48,258 received in 2024. These payments were reported across 172 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($147,392).
As a Medicare-enrolled provider, Backes has provided services to 1,196 Medicare beneficiaries, totaling 2,257 services with total Medicare billing of $226,948. Data is available for 4 years (2020–2023), covering 43 distinct procedure/service records.
Ad
Practice Information
- Specialty Obstetrics & Gynecology
- Other Specialties Gynecologic Oncology
- Location Hilliard, OH
- Active Since 05/08/2007
- Last Updated 10/09/2025
- Taxonomy Code 207V00000X
- Entity Type Individual
- NPI Number 1124231998
Products in Payments
- Lenvima (Drug) $29,826
- LYNPARZA (Drug) $26,717
- ZEJULA (Drug) $16,489
- JEMPERLI (Biological) $6,000
- Rubraca (Drug) $4,914
- KEYTRUDA (Biological) $2,969
- Lucitanib (Drug) $2,112
- ELAHERE (Drug) $1,534
- Avastin (Biological) $1,195
- XPOVIO (Drug) $193.26
- TIVDAK (Biological) $134.90
- Elahere (Biological) $89.95
- Da Vinci Surgical System (Device) $47.96
- HEMOBLAST BELLOWS (Device) $14.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Obstetrics & Gynecology Doctors in Hilliard
Alyson Leeman, M.d, M.D
Obstetrics & Gynecology — Payments: $3,984
Obstetrics & Gynecology $3,984
Vicki Miller, M.d, M.D
Obstetrics & Gynecology — Payments: $2,587
Obstetrics & Gynecology $2,587
Dr. Stephanie Conway, M.d, M.D
Obstetrics & Gynecology — Payments: $2,417
Obstetrics & Gynecology $2,417
Patricia Teach, M.d, M.D
Obstetrics & Gynecology — Payments: $2,407
Obstetrics & Gynecology $2,407
Jaina Lindauer, Md, MD
Obstetrics & Gynecology — Payments: $1,852
Obstetrics & Gynecology $1,852
Karen King, M.d, M.D
Obstetrics & Gynecology — Payments: $1,177
Obstetrics & Gynecology $1,177